skip to Global Navigation Bar skip to main content

homeHome > About Us > Press Release > News


News Content
Daewoong Pharmaceutical enters into new drug candidate ‘BBT-401’ joint development and technology transfer contract with Bridgebio
Date 2018-12-19 Hit 2500
News List
Prev Daewoong Pharmaceutical attended ICAD 2018 and promoted benefit of Nabota
Next The clinical findings of Botulinum Toxin manufactured by Daewoong have been published on international journal regarding the comparison with Botox